KRAS and cancer: The well-characterized mutagenic sequence in CRC begins with an inactivating mutation in the APC gene, a key downregulator of the Wnt/β-catenin proliferative pathway, and continues with the acquisition of subsequent mutations of oncogenes, such as KRAS, PI3KCA, SMAD4, and TP53, forming a malignant tumor [86].